Normalization of prolactin with aripiprazole in a patient with psychotic depression and a comorbid pituitary microadenoma

Psychosomatics

Volumn 48, Issue 4, 2007, Pages 350-351

  Steinhagen, Christine K ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CITALOPRAM; PROLACTIN; RISPERIDONE; TOPIRAMATE;

ADULT; ARTICLE; CASE REPORT; COMORBIDITY; DEPRESSIVE PSYCHOSIS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GALACTORRHEA; HUMAN; HYPERPROLACTINEMIA; HYPOPHYSIS ADENOMA; PATIENT COMPLIANCE; PROLACTIN BLOOD LEVEL; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 34347256405     PISSN: 00333182     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.psy.48.4.350     Document Type: Letter

References (4)

1. Stahl SM: Psychopharmacology of Antipsychotics. London, UK, Martin Dunitz, Ltd., 1999
2. Misra M, Papakostas GI, Klibanski A: Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism. J Clin Psychiatry 2004; 65:1607-1618
3. Endocrine and Metabolic Diseases Information Service: Prolactinoma. http://www.Endocrine.niddk.nih.gov/pubs/prolact/prolact.htm; accessed Feb 25, 2006
4. Potkin SG, Saha AR, Kujawa MJ, et al: Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs. placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003; 60:681-690